Finally, CRISPR genome editing established the functional impact of these regions, demonstrating that deleting distinct peaks (e.g., peaks 8 and 9 for DPEP1 and peaks 8 and 12 for CHMP1A) directly and specifically altered the expression of each gene, thereby validating their roles as key effector genes in kidney disease. This evidence concerns the gene CHMP1A and kidney disorder.